- Short report
- Open Access
Correlation between HIV viral load and aminotransferases as liver damage markers in HIV infected naive patients: a concordance cross-sectional study
© Mata-Marín et al; licensee BioMed Central Ltd. 2009
- Received: 18 September 2009
- Accepted: 30 October 2009
- Published: 30 October 2009
Abnormalities in liver function tests could be produced exclusively by direct inflammation in hepatocytes, caused by the human immunodeficiency virus (HIV). Mechanisms by which HIV causes hepatic damage are still unknown. Our aim was to determine the correlation between HIV viral load, and serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) as markers of hepatic damage in HIV naive infected patients.
We performed a concordance cross-sectional study. Patients with antiviral treatment experience, hepatotoxic drugs use or co-infection were excluded. We used a Pearson's correlation coefficient to calculate the correlation between aminotransferases serum levels with HIV viral load. We enrolled 59 patients, 50 men and 9 women seen from 2006 to 2008. The mean (± SD) age of our subjects was 34.24 ± 9.5, AST 37.73 ± 29.94 IU/mL, ALT 43.34 ± 42.41 IU/mL, HIV viral load 199,243 ± 292,905 copies/mL, and CD4+ cells count 361 ± 289 cells/mm3. There was a moderately strong, positive correlation between AST serum levels and HIV viral load (r = 0.439, P < 0.001); and a weak correlation between ALT serum levels and HIV viral load (r = 0.276, P = 0.034); after adjusting the confounders in lineal regression model the correlation remained significant. Our results suggest that there is an association between HIV viral load and aminotransferases as markers of hepatic damage; we should improved recognition, diagnosis and potential therapy of hepatic damage in HIV infected patients.
- Human Immunodeficiency Virus
- Human Immunodeficiency Virus Patient
- Hepatic Damage
- Liver Steatosis
In HIV infected patients, the increase in hepatic enzymes could be secondary to multiple factors such as alcoholism, lipid lowering drugs, co-infection with hepatitis viruses, or hereditary diseases; in addition, it has been proposed that HIV causes a direct damage over hepatic cells [4–9]. Many factors are associated with hepatic damage: antiretroviral treatment, co-infections with hepatitis B or C virus, opportunistic infections as citomegalovirus, mycobacterium, leishmaniasis, or tumors (lymphoma and Kaposi's sarcoma), cholangitis associated to parasites (cryptosporidiosis and microsporidiosis) and toxicity related with non antiretroviral drugs (trimetoprim and other antibiotics).
Abnormalities in liver function tests could be produced exclusively by direct inflammation in hepatocytes, caused by the virus. Mechanisms by which HIV causes hepatic damage are still unknown, but the most important mechanisms could be apoptosis (induced by caspases 2, 7 and 8) and mitochondrial dysfunction with decreasing in mitochondrial DNA in several tissues; another injury mechanism is permeability alteration in mitochondrial membrane by HIV proteins which stimulate an inflammatory response [9–16].
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are hepatic enzymes that could be used as markers of hepatocellular injury .
The purpose of the study was to determine the correlation between HIV viral load, with serum levels of AST and ALT as markers of hepatic damage in HIV naïve infected patients.
We performed a concordance cross-sectional study in which HIV infected naïve patients without opportunistic or co-infections at the moment of the evaluation were included. We enrolled patients seen at the Hospital de Infectología, "La Raza" National Medical Center in Mexico City from January 2006 to September 2008. Patients with recent diagnosis of HIV were eligible for the study if they were between the ages of 18 and 65 years old with negative serology to hepatitis B or C. Patients were excluded if they had alcohol consumption during the last three months or had suffered any kind of opportunistic disease or co-infection.
We ascertained patients' general attributes (age, sex), medical history, risk factors, medications, height, weight, vital signs, HIV infection confirmed by ELISA and Western-blot; and the following laboratory tests: blood cells count, bleeding times, blood chemistry, liver function tests and CD4+ cells count were obtained. In addition TORCH panel and VDRL were requested; HIV viral load was measured using reverse-transcriptase polymerase chain reaction (RT-PCR) test, with a detection limit lower than < 50 copies/ml.
Medical history and physical examination were performed in order to exclude any kind of opportunistic infection or definitory AIDS disease.
The strength of relationship between HIV viral load and AST and ALT was estimated by a Pearson correlation coefficient. To adjust for the effects of potential confounders, we used a linear regression model. The statistical significant difference was considered when p-value was less than 0.05.
Basal characteristics of 59 HIV naïve infected patients
Mass corporal index (kg/m2)
Sexual partners number
Platelets × 10-9/liter
Leucocytes × 10-9/liter
HIV viral load (copies/mL)
Correlation of HIV viral load with AST and ALT
Adjusting for age, cholesterol, triglycerides and CD4+ cells count in a multivariable linear regression model did not affect the results. HIV viral load and AST remain significant (p = 0.002) either do ALT (p = 0.021)
Our results suggest the possibility that in HIV naïve infected patients, liver injury could be the effect of HIV per se at least partially. It was found a positive correlation between HIV viral load and aminotrasferases as liver damage markers in naïve patients without any kind of opportunistic diseases or co-infections. There was a stronger positive correlation between AST and HIV viral load than with ALT, probably due to other tissues injury (muscle, lung, and kidney). We explain our results by effect of apoptosis induced by the viral proteins such as Tat, Nef, Vpr, protease and gp120 in different cell groups. These findings support partially the theories of liver damage due to mitochondrial disturbance and the stimulation of the caspases cascade in the induction of apoptosis.
These results indicate that clinicians should consider monitoring aminotransferases levels in all HIV patients including those without antiretroviral experience. Based in our results, it is possible that patients with an increase in aminotransferases could be potentially benefited with HAART.
There are few studies assessing liver injury associated to HIV; most of them are basic designs trying to find molecular mechanisms of liver damage [13–15]; other studies evaluate liver damage induced by the association of hepatitis C virus and HIV.
Our findings are consistent with those of Ejilemele et al., reporting common abnormalities of liver enzymes in HIV patients; however, they only describe patterns of liver injury and they didn't establish strength of relationship between HIV viral load and liver enzymes .
Sulkowski et al., examined liver tissue from 112 antiretroviral experienced HIV-HCV co-infected patients; 60% had no evidence of histologic liver steatosis, and only 18% had steatosis with more than 5% hepatocytes affected, but they didn't evaluate HIV mono-infected naïve patients .
Unfortunately the sample we studied was small; and that increases the possibility of a higher random error. Another limitation is the cross-section design which is unable to measure all potential confounders; however, in analysis, confounding factors were controlled; then, we consider results are valid for our population.
According to our results there is a correlation between the HIV viral load, and aminotransferases serum levels in HIV infected naïve patients. Liver function tests should be monitorized closely in these patients; and we suggest evaluating early start of antiretroviral treatment in HIV infected patients with severe liver damage regardless of CD4+ cell count.
It is necessary to perform a study including more patients, using direct or indirect liver damage measures (biopsy, fibrotest or transient elastography) to improve recognition, diagnosis and management. Finally, future prospective research to study antiretroviral therapy effects on reducing aminotransferases levels in these patients should be developed.
The authors wish to acknowledge to the study participants and who contributed to this study.
- Fauci AS: Twenty-five years of HIV/AIDS. Science 2006, 313: 409. 10.1126/science.1131993View ArticlePubMedGoogle Scholar
- Blacker J: The impact of AIDS on adult mortality: evidence from national and regional statistics. AIDS 2004,18(supl 2):S19-S26. 10.1097/00002030-200406002-00003View ArticlePubMedGoogle Scholar
- UNAIDS: 2006 AIDS Epidemic update: Geneva (Seitzerland): Joint United Nations Programme on HIV/AIDS, November 2006[http://www.unaids.org]
- Jain MK: Drug-induced liver injury associated with HIV medications. Clin Liver Dis 2007, 11: 615-39. 10.1016/j.cld.2007.06.008View ArticlePubMedGoogle Scholar
- Walker UA: Antiretroviral therapy induced liver alterations. Curr Opin HIV AIDS 2007, 2: 293-8. 10.1097/COH.0b013e328122dbaaView ArticlePubMedGoogle Scholar
- Vogel M, Rockstroh J: Hepatotoxicity and liver disease in the context of HIV therapy. Curr Opin HIV AIDS 2007, 2: 306-13. 10.1097/COH.0b013e3281ca6fd2View ArticlePubMedGoogle Scholar
- Mocroft A, Phillips AN, Soriano V, Ledergerber B, Kirk O, Vinogradova E, Reiss P, Katlama C, Phillips AN, Lundgren JD, EuroSIDA Study Group: Reasons for stopping antiretroviral regimen: Increased incidente of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005, 21: 743-52. 10.1089/aid.2005.21.743View ArticlePubMedGoogle Scholar
- Cooper CurtisL: HIV antiretroviral medications and hepatotoxicity. Curr Opin HIV AIDS 2007, 2: 466-73. 10.1097/COH.0b013e3282f0dd0bView ArticlePubMedGoogle Scholar
- Pol S, Lebray P, Vallet-Pichard A: HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. Clin Infect Dis 2004,38(suppl 2):S65-S72. 10.1086/381499View ArticlePubMedGoogle Scholar
- Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, Harris M, Harrigan PR, O'Shaughnessy MV, Montaner JS: Changes in mitocondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002, 346: 811-20. 10.1056/NEJMoa012035View ArticlePubMedGoogle Scholar
- Miro O, López S, Martínez E, Pedrol E, Milinkovic A, Deig E, Garrabou G, Casademont J, Gatell JM, Cardellach F: Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals. Clin Infect Dis 2004, 39: 710-6. 10.1086/423176View ArticlePubMedGoogle Scholar
- Casula M, Bosboom-Dobbelaer I, Smolders K, Otto S, Bakker M, de Baar MP, Reiss P, de Ronde A: Infection with HIV-1 induces a decrease in mt-DNA. J Infect Dis 2005, 191: 1468-71. 10.1086/429412View ArticlePubMedGoogle Scholar
- Jacotot E, Ravagnan L, Loeffler M, Ferri KF, Vieira HL, Zamzami N, Costantini P, Druillennec S, Hoebeke J, Briand JP, Irinopoulou T, Daugas E, Susin SA, Cointe D, Xie ZH, Reed JC, Roques BP, Kroemer G: The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med 2000, 191: 33-46. 10.1084/jem.191.1.33PubMed CentralView ArticlePubMedGoogle Scholar
- Balasubramanian A, Koziel M, Groopman JE, Ganju RK: Molecular mechanism of hepatic injury in coinfection with hepatitis C virus and HIV. Clin Infect Dis 2005,41(Supl 1):S32-S37. 10.1086/429493View ArticlePubMedGoogle Scholar
- Gross A, Jockel J, Wei MC, Korsmeyer SJ: Enforced dimerization of Bax results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 1998, 17: 3878-85. 10.1093/emboj/17.14.3878PubMed CentralView ArticlePubMedGoogle Scholar
- Guaraldi G, Squillace N, Stentarelli C, Orlando G, D'Amico R, Ligabue G, Fiocchi F, Zona S, Loria P, Esposito R, Palella F: Nonalcoholic fatty liver disease in HIV infected-patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008, 47: 250-7. 10.1086/589294View ArticlePubMedGoogle Scholar
- Zechini B, Pasquazzi Z, Aceti A: Correlation of serum aminotransferases with HCV RNA levels and histological findings in patients with chronic hepatitis C: the role of serum aspartate transaminase in the evaluation of disease progression. Eur J Gastroenterol Hepatol 2004, 16: 891-6. 10.1097/00042737-200409000-00013View ArticlePubMedGoogle Scholar
- Ejilemele AA, Nwauche Ca, Ejele OA: Pattern of abnormal liver enzymes in HIV patients presenting al a Nigerian Tertiary Hospital. Níger Postgrad Med J 2007, 14: 306-9.PubMedGoogle Scholar
- Bruno R, Sacchi P, Puoti M, Maiocchi L, Patruno SF, Cima S, Filice G: Pathogenesis of liver damage in HCV-HIV patients. AIDS Rev 2008, 10: 15-24.PubMedGoogle Scholar
- Sulkowski M, Mehta S, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL: Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005, 19: 585-92. 10.1097/01.aids.0000163935.99401.25View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.